BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Point mutations in the kinase domain of BCR-ABL are the most common mechanism of drug resistance in chronic myeloid leukemia (CML) patients treated with ABL kinase inhibitors, including imatinib. It has also been shown in vitro that mutations outside the kinase domain in the neighboring linker, SH2, SH3, and Cap domains can confer imatinib resistance. In the context of ABL, these domains have an autoinhibitory effect on kinase activity, and mutations in this region can activate the enzyme. To determine the frequency and relevance to resistance of regulatory domain mutations in CML patients on imatinib, we screened for such mutations in a cohort of consecutive CML patients with various levels of response. Regulatory domain mutations were detected in 7 of 98 patients, whereas kinase domain mutations were detected in 29. One mutation (T212R) conferred in vitro tyrosine kinase inhibitor resistance and was associated with relapse, whereas most other mutations did not affect drug sensitivity. Mechanistic studies showed that T212R increased the activity of ABL and BCR-ABL and that T212R-induced resistance may be partially the result of stabilization of an active kinase conformation. Regulatory domain mutations are uncommon but may explain resistance in some patients without mutations in the kinase domain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Cited by
ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity
Colicelli, J. (2010) · Science Signaling · doi:10.1126/scisignal.3139re6 · Cited by 347
Conformational states dynamically populated by a kinase determine its function
Xie, T., Saleh, T., Rossi, P., & Kalodimos, C. G. (2020) · Science · doi:10.1126/science.abc2754 · Cited by 266
Chan, W. W., Wise, S. C., Kaufman, M. D., Ahn, Y. M., Ensinger, C. L., Haack, T., Hood, M. M., Jones, J., Lord, J. W., Lu, W. P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.003 · Cited by 208
“…mutations recovered that are known to destabilize the inactive conformation of BCR-ABL1 towards its active, Type I conformation (Azam et al., 2003; Sherbenou et al., 2010), nor were there mutations identified in the switch control amino acids E282/R386, which may be required for assembly of the…”
BackgroundAlves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.03.018 · Cited by 105
Metadata
- Authors
- Sherbenou, D. W., Hantschel, O., Kaupe, I., Willis, S., Bumm, T., Turaga, L. P., Lange, T., Dao, K.-H., Press, R. D., Druker, B. J., Superti-Furga, G., & Deininger, M. W.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-10-28
- Volume
- 116
- Issue
- 17
- Pages
- 3278-3285
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2013477475
- Cited by
- 83
- References
- 2
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. https://app.cochat.ai/papers/10.1182/blood-2008-10-183665
- The paper
- Sherbenou, D. W., Hantschel, O., Kaupe, I., Willis, S., Bumm, T., Turaga, L. P., Lange, T., Dao, K.-H., Press, R. D., Druker, B. J., Superti-Furga, G., & Deininger, M. W. (2010). BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood. https://doi.org/10.1182/blood-2008-10-183665
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.